Re-Irradiation for Recurrent Glioblastoma Multiforme

Patients requiring re-irradiation for recurrent glioblastoma multiforme (GBM) may benefit from individualized therapy. This study aimed to identify predictors of survival and contribute to treatment personalization. In 28 patients with recurrent GBM, nine factors were analyzed for associations with...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-12, Vol.40 (12), p.7077-7081
Main Authors: Rades, Dirk, Witteler, Jaspar, Leppert, Jan, Schild, Steven E
Format: Article
Language:English
Subjects:
Brain cancer
Female
Glioblastoma
Glioblastoma - mortality
Glioblastoma - radiotherapy
Humans
Irradiation
Male
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Radiation therapy
Re-Irradiation - methods
Retrospective Studies
Survival
Survival Analysis
Trends
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients requiring re-irradiation for recurrent glioblastoma multiforme (GBM) may benefit from individualized therapy. This study aimed to identify predictors of survival and contribute to treatment personalization. In 28 patients with recurrent GBM, nine factors were analyzed for associations with survival: Main location and type of recurrence, Karnofsky performance score (KPS), age, gender, interval between primary radiotherapy and recurrence, gross total resection (GTR), equivalent dose in 2-Gy fractions (EQD2) of re-irradiation and cumulative EQD2 of primary and re-irradiation. On univariate analyses, GTR (p=0.047), EQD2 ≥30 Gy (p=0.029) and cumulative EQD2 ≥90 Gy (p=0.023) were significantly associated with better survival; frontal location (p=0.119) and KPS 80-100% (p=0.067) showed trends. In multivariate analyses, frontal location (p=0.032) and cumulative EQD2 ≥90 Gy (p=0.038) were significant; KPS 80-100% (p=0.110) and EQD2 ≥30 Gy (p=0.083) showed trends. Predictors of survival after re-irradiation for recurrent GBM were identified that can help when designing personalized treatments. Use of irradiation with EQD2 ≥30 Gy appeared superior to lower doses.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14735